Booz Allen and Corsha join forces to secure the machine identity layer – a rapidly growing and underserved market – for mission-critical operational systems

WASHINGTON, July 10, 2025 — Corsha, the first and only Machine Identity Provider (mIDP) purpose-built to secure machine-to-machine (M2M) communication across operational systems and critical infrastructure, today announced a strategic investment from Booz Allen Ventures, the corporate venture capital arm of Booz Allen Hamilton. The investment will accelerate Corsha’s mission to deliver secure machine identity and access management (IAM) for operational environments powering advanced manufacturing and industrial systems, national defense, and critical infrastructure.

The investment by Booz Allen underscores the urgent need for strong authentication and dynamic machine identity as federal agencies and enterprises race to implement Zero Trust architectures across increasingly autonomous, interconnected systems. Corsha’s patented machine identity platform (mIDP) ensures that every automated connection is fully verified and authorized at machine speed and scale.

“Our world is shifting rapidly toward autonomy, automation, and connected machines. That future demands a new kind of identity infrastructure, purpose-built for mission systems and critical infrastructure,” said Anusha Iyer, CEO and Founder of Corsha. “Booz Allen brings unmatched scale, mission expertise, and deep roots in national security. We’re thrilled to partner with them to expand the impact of our machine identity platform and secure the operational systems that power the world.”

As an advanced technology company and the leading provider of AI and cybersecurity to the federal government, Booz Allen is building solutions in agentic AI, autonomous mission systems, and Zero Trust. Corsha delivers a critical building block as the first identity provider purpose-built for machines at a time when machines outnumber humans 80:1. This investment builds on Corsha’s momentum of its $18 million Series A-1 round, which includes investments from Sinewave, Razor’s Edge Ventures, and Ten Eleven Ventures.

“Corsha stands out for its technical depth, mission focus, and elegant solution to a growing problem in operational cybersecurity,” said Chris Woods, Investor at Booz Allen Ventures. “Corsha’s broad application in the non-human identity space excites us, beginning with their approach to securing machine identities aligns perfectly with the Department of Defense’s strategic priorities around Zero Trust, autonomy, and resilience. We believe Corsha is uniquely positioned to become foundational infrastructure for next-generation mission systems.”

As federal agencies race to meet Zero Trust mandated deadlines, they need fine-grained access control not just for users, but also for the machines that power modern defense and industrial systems. Corsha’s mIDP platform delivers:

• Strong, cryptographic machine identities for every system
• Dynamic authentication and access at every connection
• Automated lifecycle management for millions of machine identities
• Secure deployments in diverse environments from cloud to air-gapped, hybrid, and industrial

“Identity is the new perimeter, and that starts with machines,” said David Forbes, Director of Cyber-Physical Defense at Booz Allen and leader of the firm’s Zero Trust for operational technology efforts. “As operational environments become more dynamic and more connected, Corsha’s platform delivers the kind of adaptive, identity-first machine security that Zero Trust requires. Booz Allen sees tremendous potential to operationalize this approach across mission-critical domains to help safeguard the nation.”

This investment from Booz Allen supports a new phase of growth for Corsha as it works to embed trusted machine identity into the fabric of modern infrastructure and automated systems, from manufacturing and energy to space, defense, and critical infrastructure.

To learn more about Corsha’s platform and mission, visit corsha.com.

About Corsha
Corsha is the first and only machine identity platform purpose-built to secure operational systems and critical infrastructure. Corsha’s patented Machine Identity Provider (m-IdP) allows enterprises to securely connect systems, move data, and automate with confidence from anywhere to anywhere. Corsha is backed by leading venture capital firms including SineWave, Razor’s Edge, Ten Eleven Ventures, and Booz Allen Ventures.

SOURCE Corsha

VAUGHAN, ON, July 9, 2025 – Minus Waste Solutions, a leading provider of sustainable food waste recycling and resource recovery services, is pleased to announce it has secured a significant growth equity investment from the Canada Business Growth Fund (CBGF).

This strategic partnership will support Minus Waste Solutions’ mission to transform food waste into valuable resources while expanding its footprint across Canada and beyond. The investment will accelerate the company’s plans to scale operations, enhance its technology platforms, and pursue strategic acquisitions in the waste management sector.

“We are thrilled to partner with CBGF as we take Minus Waste Solutions into its next phase of growth,” said Leonidas Anagnostakos, President of Minus Waste Solutions. “This investment further validates our business model and our team’s dedication to providing innovative, sustainable solutions for food waste diversion. Together with CBGF, we are well positioned to drive meaningful impact in advancing a circular economy.”

CBGF invests in ambitious Canadian companies with proven track records and strong growth potential. “Minus Waste Solutions has built a highly differentiated and scalable platform in the waste management industry,” said Dale Tingley, Co-Managing Partner at Canada Business Growth Fund. “We look forward to supporting their continued growth and helping them achieve their vision for a more sustainable future.”

Minus Waste Solutions operates a processing facility in Vaughan, Ontario, serving a growing list of commercial, industrial, and institutional clients. With a focus on innovation, the company provides customized programs that divert organic waste from landfill, turning it into animal feed, renewable energy, and other value-added products.

About Minus Waste Solutions
Minus Waste Solutions is a Canadian leader in food waste recycling and resource recovery. Through innovative processes and a commitment to sustainability, the company helps businesses reduce their environmental footprint and create value from food waste streams.

About Canada Business Growth Fund (CBGF)
The Canadian Business Growth Fund (CBGF) provides long-term, patient, minority capital to ambitious entrepreneurs to fund the growth and expansion of mid-market businesses with investments between $5 and $20 million. An evergreen investment fund with capital commitments of $545 million, CBGF is committed to long-term partnerships with the companies it invests in. As part of its mission to drive growth, CBGF connects business leaders and sector experts to help its partner businesses achieve their full potential.

Website: www.minussolutions.com

SOURCE Minus Waste Solutions

PHOENIX, July 9, 2025 — Trinity Capital Inc. (NASDAQ: TRIN) (“Trinity Capital”), a leading alternative asset manager, today announced the commitment of $35 million in growth capital to INSHUR, a leader in innovative insurance solutions for the on-demand economy.

Operating globally, INSHUR provides commercial insurance for on-demand mobility drivers, fleet operators, and delivery platforms across the mobility and delivery sectors. The company recently surpassed 1 million policies sold in the U.K., one of its core markets. Its platform offers a personalized suite of tech-enabled insurance products, providing flexible coverage and protection that adapts to the distinct needs of on-demand drivers.

“INSHUR understands the unique challenges of drivers across the on-demand economy and is delivering tailored insurance solutions designed to specifically meet those needs,” said Jack McNamara, Director of Tech Lending at Trinity Capital. “We are excited to partner with their team as they continue to scale operations and deliver accessible coverage to drivers around the world.”

This capital will help grow INSHUR’s continued expansion across the U.S., advance its research into AI technologies for underwriting and real-time pricing, develop new solutions for the autonomous vehicle market, and expand partnerships with platforms offering on-demand services.

“With a consistent >50% CAGR since 2023, rapid international growth and a clear path to profitability, this raise helps INSHUR continue to cement its position as the leader in insurance solutions for the on-demand economy. Trinity Capital’s support will enable us to accelerate our U.S. and global expansion, and to leverage our deep insurance and technology expertise to further develop our service offering into innovative and upcoming areas such as autonomous vehicles,” said Dan Bratshpis, CEO and Co-founder of INSHUR.

Burch & Company, Inc., member FINRA/SIPC, through their registered investment banking agent associated with Edge OMC, served as a sole advisor to INSHUR in connection with the transaction.

About Trinity Capital Inc.
Trinity Capital Inc. (NASDAQ: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies. With five distinct business verticals–Sponsor Finance, Equipment Finance, Tech Lending, Asset-Based Lending, and Life Sciences–Trinity Capital stands as a long-term trusted partner for innovative companies seeking tailored debt solutions. Headquartered in Phoenix, Arizona, Trinity Capital’s dedicated team is strategically located across the United States and in London (UK). For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn and X (@trincapital).

About INSHUR
Multi award-winning INSHUR is the fastest-growing global leader in insurance solutions for the on-demand economy, making coverage fair and accessible for drivers and supporting the world’s biggest platform and insurance partners.

Founded in 2016 and with offices in US, UK and Netherlands, INSHUR provides embedded insurance solutions and complementary technology integrations for digital platform providers such as Uber and Amazon. Thanks to its unrivaled underwriting capabilities and exceptional claims handling, INSHUR offers a personalized suite of products that protects the wellbeing of on demand livery and delivery drivers, providing flexible coverage and protection which adapts to the job – helping them stay on the road and keep earning.

As an Uber preferred driver insurance provider in certain European and North American markets, INSHUR is constantly adding to its growing list of platform partners who recognize and value INSHUR for its seamless integration abilities and smooth customer onboarding and relationship management. https://inshurgroup.com/

About Edge OMC
Edge OMC is a boutique investment bank that helps technology and lower mid-market companies raise $20–$250 million in growth capital. Acting as a “Capital Markets-as-a-Service” partner, Edge manages the full capital raise process, allowing CEOs and CFOs to focus on scaling their businesses. With deep expertise in capital markets and company-building, Edge delivers tailored advisory solutions that drive long-term value.

Certain Principals of Edge OMC are licensed investment banking agents, offering securities related services through Burch & Company, Inc., 4151 North Mulberry Drive, Suite 235, Kansas City, MO 64116, member FINRA SIPC.  Burch and Edge OMC are unaffiliated entities.

SOURCE Trinity Capital Inc.

Phoenix-based startup’s proprietary “Flavor-First” technology preserves taste while reducing alcohol content

PHOENIX, July 9, 2025 — ALTR, a pioneering beverage technology company, today announced the successful completion of a $5 million seed funding round to commercialize its groundbreaking alcohol removal technology. The company’s proprietary “Flavor-First” process enables the creation of premium low-alcohol drinks that maintain the full sensory experience.

Backed by leading investors in the beverage and technology sectors, French investment fund Demeter led the round, with participation from Suntory Global Spirits, Techmind, AZ Venture Capital Inc., FTW Ventures, Bluestein Ventures, Solvable, and Xinomavro. The funding will accelerate product development and expand ALTR’s partnerships with some of the world’s best wineries as consumer demand for mindful drinking options continues to surge.

Technology That Preserves What Matters Most

With its proprietary Flavor-First alcohol removal technology, ALTR has cracked the code. Developed specifically for the compounds and structure of alcoholic beverages and engineered for precision ethanol removal at a molecular level, ALTR’s method is non-destructive and non-intrusive—preserving the full sensory experience: flavor, structure, and mouthfeel. Starting with the wine industry, this breakthrough allows the creation of truly premium low-alcohol offerings that honor the craftsmanship of traditional winemaking.

“ALTR is on a quest to remove the stigma of less alcohol for both the consumer and the beverage maker, pairing cutting-edge technology with craft traditions,” said Richard Schatzberger, ALTR’s Founder and CEO.

Science Meets Craftsmanship

ALTR’s team combines world-leading membrane scientists with renowned winemakers to ensure both technical precision and sensory excellence. The company’s low-environmental-impact process aligns with growing sustainability demands in the beverage industry.

Through deep collaborations with wineries, strategic industry partnerships, and a strong commitment to brand-led consumer education, ALTR is setting the standard for what comes next.

“We don’t make ‘de-alcoholized wine’—we just make great wine, it’s that simple,” said Schatzberger. This philosophy is why the technology is now in the hands of some of the most famous winemakers alongside innovative new brands.

Addressing Industry Transformation

This is not a passing trend—it is a necessary transformation. As the wine industry grapples with changing demographics, evolving consumption patterns, and the impact of climate change driving alcohol levels higher, ALTR is leading the charge. By proving that innovation and tradition can coexist, ALTR is paving the way for a more balanced future in wine.

Advanced Science for Amazing Times

This innovation is designed to foster deeper human connection by preserving the social rituals of drinking while reducing the negative impacts of the alcohol molecule.

“We are ushering in the Next Era of Wine,” said Schatzberger. “An era where quality, choice, and well-being are no longer at odds—but finally in harmony.”

Media Contact:

Taylor Foxman

609-432-2237

[email protected]

Elisa Calvello

Director of Strategy and Marketing for ALTR

646.508.3715

[email protected]

SOURCE ALTR

• Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others
• Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention  
• Proceeds will support clinical development of Actithera’s fibroblast activation protein (FAP)-targeting candidate and pipeline expansion

OSLO, Norway and CAMBRIDGE, Mass., July 9, 2025 — Actithera, a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs), today announced the close of an oversubscribed $75.5 million Series A financing round. The financing will support the advancement of Actithera’s lead FAP asset into clinical development in multiple indications, while also enabling the continued development of its proprietary RLT discovery platform and preclinical pipeline.

The round was co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital, with additional participation from Bioqube Ventures, Innovestor’s Life Science Fund, Investinor, Surveyor Capital (a Citadel company), and second founding investor, Arkin Bio Ventures II.

The Company’s discovery platform combines rational drug design with radiochemistry to create novel small molecule radioligands that overcome current limitations in radiopharmaceutical development. Its three-pillar platform includes first-in-class covalent targeting strategies, designed to optimize tumor residence time, while ensuring rapid systemic clearance – improving precision, safety, and efficacy. Two additional proprietary approaches further support compound differentiation and improve tumor residence time and selectivity. This platform was validated through Actithera’s work on FAP, a high-value theranostic target known for being difficult to drug with molecules that maintain prolonged tumor residency. These efforts have resulted in a FAP-directed RLT development candidate with best-in-class potential due to its optimal pharmacokinetic profile and tumor specificity.

Dr. Andreas Goutopoulos, founder and CEO, brings over 25 years of pharmaceutical and biotech industry experience, including a track record of more than a dozen development candidates. His background includes over a decade of discovery leadership at EMD Serono, where he led medicinal chemistry. In his role as Entrepreneur-in-Residence (EIR) at M Ventures, he led the scientific efforts of and supported a number of oncology small molecule biotechs. At Actithera, he is pioneering a chemistry-driven, precision approach to RLTs by integrating novel covalent-targeting chemistries, rational drug design principles and an isotope-agnostic philosophy.

“We set out to bring structure-based and kinetics-driven thinking from small molecule drug design into the world of radiopharmaceuticals,” said Dr. Andreas Goutopoulos. “This oversubscribed Series A, backed by a truly global and experienced investor syndicate, is strong validation of our approach. We engineer our radioconjugates for extended retention within tumors, making them ideally suited for longer-lived radionuclides and ultimately delivering more convenient dosing schedules and enhanced efficacy and safety for patients.“

Karl Naegler, incoming Board member and Partner at Sofinnova Partners, noted: “Actithera is applying Big Pharma discipline to an emerging field with enormous potential. Its radioligand therapies represent a meaningful shift in oncology, with the opportunity to redefine the therapeutic index. We’re excited to support that vision.”

Roger Franklin, incoming Board member and Partner at Hadean Ventures, added: “Actithera stands out as one of the most thoughtfully constructed radiopharma platforms we’ve seen, combining smart molecular design with a deep understanding of tumor biology and clinical need. The team’s work to align pharmacokinetics with therapeutic effect could transform how patients experience and benefit from radioligand therapies.”

Therese Liechtenstein, incoming Board member and Investment Director at 4BIO Capital, added: “We are honored to support Actithera, whose molecules address key challenges in the nascent radioligand therapies space; a large therapeutic window through high tumor retention and low systemic exposure, applied to a lead program that has significant pan-tumor therapeutic potential.”

Hakan Goker, current Chairman of Actithera, and Managing Director at M Ventures, said: “We are excited to see Actithera evolve from the one-person ideation we seeded with Andreas and Arkin to the transatlantic company it has become today. The innovative chemistry platform built and the first-in-class approach on FAP have the potential for a large impact in the RLT field and a significant benefit for patients. We welcome the new investor group and Board members to the company aligned with this bold vision of building the next generation of RLTs.” 

As part of the Series A financing, Roger Franklin, Partner at Hadean Ventures, Karl Naegler, Partner at Sofinnova Partners, Therese Liechtenstein, Investment Director at 4BIO Capital, and Debbie Dumont, Managing Partner at Bioqube Ventures will join the Actithera Board of Directors, including Noga Yerushalmi, Investment Director at M Ventures, who is currently on the Board.

About Actithera
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology. Learn more at www.actithera.com and on LinkedIn.

About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. From its headquarters in the Netherlands and offices in Germany, USA and Israel, M Ventures invests globally in transformational ideas driven by innovative entrepreneurs. Taking an active role in its portfolio companies, M Ventures teams up with management teams and co-investors to translate scientific discoveries into commercial success. M Ventures focuses on investing along the two extensive investment areas Biotechnology and Technology covering the areas of Healthcare drug development, Life Science tools, Electronics, and Frontier Technology & Sustainability. For more information, visit m-ventures.com

About Hadean Ventures
Hadean Ventures is a European life science fund manager that invests in life science companies across Europe with a particular focus on the Nordic region. Hadean Ventures is managing funds backed by leading European and US-based, private and institutional investors. Hadean Ventures has offices in Oslo and Stockholm and collaborates with world-class academic institutions and start-up hubs across the region.
https://www.hadeanventures.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.

About 4BIO Capital
4BIO Capital (“4BIO”) is an international venture capital firm focused on investing in advanced therapies and emerging modalities, to unlock the treatments of the future. 4BIO’s mission is to invest in, support, and grow early-stage companies solving technical bottlenecks that enable next generation therapeutics in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially transformative therapies for all patients. The 4BIO team comprises leading advanced therapy scientists and experienced life science investors with an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space. For more information, connect with us on LinkedIn and Twitter @4biocapital and visit www.4biocapital.com.

About Bioqube Ventures
Bioqube Ventures is an early-stage global life sciences investment firm with offices in Belgium and San Diego, CA. We source, finance and develop first-in-class and/or best- in-class therapeutics to treat patients suffering from debilitating diseases. With our product focused investment strategy, we aim to build balanced portfolios spanning company creation, preclinical and early clinical investments.
https://www.bioqubeventures.com/

SOURCE Actithera

• Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Bio, Base4 Capital and others
• Dr. Emilio Emini, former SVP of Vaccine Research and Development at Pfizer, SVP of Research at Merck, and CEO of the Bill & Melinda Gates Medical Research Institute, joins the Board of Directors

SOUTH SAN FRANCISCO, Calif., July 8, 2025 — Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in aggregate represent $1.4 trillion of value creation. The round includes participation from NFX, BOLD Capital Partners, Base4 Capital, Kendall Capital Partners, Amplify Bio, and other investors. Existing insiders increased their ownership in the round.

“Future Ventures is proud to lead Centivax’s Series A with a great syndicate of co-investors,” said lead investor Steve Jurvetson. “I have been on a quest to find a credible antiviral breakthrough for over 20 years. I first became enamored with the prospect of a universal vaccine via our philanthropy. Centivax has developed a universal shot for all forms of flu, and they have already demonstrated their universal immunity platforms in other areas, including universal antivenom. Their unique approach will hopefully lead to a historic transition to a post-pandemic era for humanity.”

The Series A will fund Centivax’s first clinical candidate, a universal flu vaccine currently in CMC development, through a Phase I clinical trial slated to begin within eight months. In addition to safety, the study will measure correlate-of-protection efficacy using the gold-standard hemagglutination inhibition (HAI) assay against a panel of more than twenty flu strains—including current 2024-2025 circulating strains, historical mismatch strains, and pandemic strains—in a direct head-to-head comparison with existing standard-of-care flu vaccines. Because the HAI assay is the same correlate-of-protection used to license seasonal flu vaccines, positive data will provide a clear benchmark demonstrating the candidate’s ability to deliver broad protection with a single vaccine. “The Phase I trial gives us the opportunity to prove the Centivax platform technology works,” said Dr. Jerald Sadoff, MD, Chief Medical Officer of Centivax. “We can demonstrate that the Centivax technology directs the immune system to focus on regions of pathogens that do not change across strains. This is valuable not just in flu, but for all rapidly mutating pathogens and other difficult targets in our portfolio.” In preclinical studies in ferrets, pigs, cows, mice, rats, and human immune organoids, the Centivax technology consistently induced universal immunity to all tested influenza viruses, including the 2024-2025 H5N1 “bird flu.”

Beyond its flagship universal-flu program, Centivax’s epitope-focusing platform enables a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom that was recently published in Cell and spotlighted by the Wall Street Journal, New York Times, Nature, and other outlets. This growing portfolio underscores the technology’s broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease. “Vaccines are already doing this. The Gardasil® vaccine, which our CMO played a key role in developing, reduced the national incidence of multiple cancer types, and was, in effect, an anti-cancer vaccine,” said Dr. Jacob Glanville, PhD, co-founder and CEO of Centivax, “The Zostavax™ vaccine, which our CMO also spearheaded, has been recently demonstrated to reduce Alzheimer’s and heart disease. We believe that universal vaccines can take us further.”

Centivax is led by CEO and founder Dr. Jacob Glanville, former founder and CEO of Distributed Bio, whose clients included Pfizer, Boehringer, Gilead, Teva, and 60 other biotechs and pharmaceutical companies and was acquired by Charles River Laboratories in 2020; Chief Medical Officer Dr. Jerald Sadoff, who previously led vaccine development at Johnson & Johnson, Merck, WRAIR, and AERAS, resulting in 14 vaccines receiving regulatory approval, including Gardasil®, Zostavax™, ProQuad®, Rotateq®, and the Janssen Jcovden COVID-19 vaccine; Chief Scientific Officer and co-founder Dr. Sawsan Youssef, who successfully exited Distributed Bio with Glanville in 2020, and whose work at Pfizer led to the clinical-stage drug sasanlimab; and co-founder and Chief Business Officer Stephanie Wisner, MBA, formerly of ARCH Venture Partners and author of Building Backwards to Biotech. The leadership team also includes Chief Innovation Officer Dr. Gusti Zeiner, Chief Operations Officer and co-founder David Tsao, and Chief Technology Officer and co-founder Dr. Nicholas Bayless.

“Universal vaccines won’t just be safer, more reliable, and more convenient medicine—their commercialization will end the pandemic era,” said Glanville. “I am particularly excited to partner with Steve Jurvetson at Future Ventures due to his track record of new industry formation based on disruptive technology. This financing positions us to deliver on the U.S. government’s stated goal of a universal influenza vaccine within five years and to extend our platform to other high-impact diseases that needlessly weigh on our medical systems and our lives.”

As part of the financing, Emilio Emini, PhD—former CEO of the Gates Medical Research Institute, Director of the Gates Foundation HIV and tuberculosis programs, and former SVP of Vaccine R&D at Pfizer and Merck—joins Centivax’s Board of Directors. Dr. Emini has been a major contributor to the development of multiple vaccines, including Prevnar, where he was responsible for its development for both pediatric and adult prevention of pneumococcal disease.

“I very much look forward to working with the Centivax team as a member of the company’s Board,” said Dr. Emini, PhD. “Centivax’s approach to the design and development of a truly universal influenza vaccine is unique and creative. As such, the approach has considerable potential for successfully achieving a goal that has proven elusive to date.”

In addition to venture backing, Centivax has secured $24 million to date in competitive, non-dilutive awards—beginning with a $2 million “Grand Challenge: End the Pandemic Threat” grant from the Bill & Melinda Gates Foundation and followed by awards from CEPI, the National Institutes of Health, the Military Infectious Diseases Research Program, the U.S. Naval Medical Research Command, and others.

“In today’s financing climate, we are proud to have assembled an exceptional syndicate of investors and an exceptional team, both of which have an impressive track record of bringing breakthrough technologies to market,” said co-founder and Chief Business Officer Stephanie Wisner. “This funding carries us through first-in-human studies—a value-inflection point that will catalyze the next phase of growth for Centivax and move the first universal flu vaccine one step closer to market.”

About Centivax
Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets. The lead clinical candidate for influenza—featured in The New Yorker, the Netflix docuseries Pandemic: How to Prevent an Outbreak, and other outlets—addresses a greater than $7 billion global flu market, with follow-on programs spanning a growing pipeline for RSV/hMPV, herpesviruses, HIV, malaria, oncology, and a universal antivenom. This growing portfolio underscores the technology’s broad potential not only to protect against a wide array of infectious diseases–including viral, bacterial, protozoan, fungal, parasitic and man-made bioterror threats–but also to improve healthspan by reducing the long-term complications these pathogens can trigger, such as cancer, autoimmune conditions, cardiovascular and neurodegenerative disease. Centivax is headquartered in South San Francisco, California. Visit www.centivax.com and follow @Centivax on X.

Media Contact
Stephanie Wisner, MBA
Chief Business Officer
[email protected] | +1 415-712-0001

SOURCE Centivax

Talent-led investment firm focuses on building executive teams and investing in growth-stage companies across aerospace, defense, alternative energy, robotics & automation, and advanced manufacturing.

LOS ANGELES, July 8, 2025 — Today marks the official launch of Unmatched Ventures, a talent-led venture firm purpose-built to invest in and scale the next generation of frontier technology and industrial innovation. Founded by Todd Gitlin, Simon Casuto, Aaron Zeeb, and Holly Rockwell, Unmatched Ventures brings a combined track record of scaling breakout companies across frontier technology, venture capital, executive search, and advisory.

Unmatched Ventures is focused on the reindustrialization of the U.S. economy and the revitalization of sectors critical to national competitiveness. The firm invests in Series A – C growth-stage companies leading advancements in:

• Aerospace and Defense
• Alternative Energy
• Robotics and Automation
• Advanced Manufacturing, including 3D printing and industrial AI

These sectors are not just ripe for innovation, they represent rapidly expanding markets:

• The global space economy is projected to grow from $418B today to $1.8T by 2035
• The defense market is expected to increase by 31%, reaching $3.9T by 2033
• Robotics and advanced manufacturing are each forecasted to more than double in size over the next five years
• The global energy transition market is set to triple, from $2.07T to $6.47T by 2032

What sets Unmatched apart is its talent-led model, pairing capital with executive search, advisory, and proprietary data on real-time company and talent movement to help founders build high-density leadership teams fast.

“Reindustrialization isn’t just an economic opportunity, it’s a national imperative,” said Holly Rockwell, Founding Partner. “We believe the future will be built by the companies reshaping how things are made, powered, and protected. At Unmatched, we’re here to back these companies with capital, with people, and with execution firepower.”

To learn more about Unmatched Ventures, visit www.unmatched.ventures or reach out to [email protected].

Media Contact:
 Holly Rockwell
 Founding Partner
 [email protected]
 www.unmatched.ventures

SOURCE Unmatched Ventures, LLC

With the support of GTCR, Clear Capital will continue to deliver innovative technology, analytics and data solutions to the mortgage and real estate industries

CHICAGO, July 8, 2025 — GTCR, a leading private equity firm, announced today that it has made a significant investment in Clear Capital (the “Company”), a leading national real estate analytics, data solutions, and valuation technology company. GTCR is partnering in the investment with Clear Capital’s co-founder and CEO Duane Andrews and its strong existing management team to further invest in the Company’s growth and strengthen its market leadership. The transaction represents Clear Capital’s first outside investment, with GTCR becoming the Company’s majority shareholder and Mr. Andrews retaining substantial equity ownership.

Headquartered in Reno, Nevada, Clear Capital is a leading provider of valuation technology, analytics and data solutions for the mortgage and real estate industries. Since its founding in 2001, Clear Capital has consistently led the industry in developing innovative technology-driven solutions for customers across the mortgage and real estate value chains. Today, Clear Capital is the industry’s leading provider of alternative valuations and technology-powered appraisals, leveraging its advanced technology platform, innovative products and deep customer relationships to differentiate itself in the marketplace. Clear Capital’s product suite supports over five million real estate and housing finance transactions annually, and its digital floor plan offering, CubiCasa, is used in approximately 30% of all new real estate listings nationwide.

GTCR will work closely with Mr. Andrews and Clear Capital’s management team to enhance and expand the Company’s leading valuation and data offerings, further invest in its technology platform and infrastructure, and accelerate M&A activity. The investment will also support the continued growth and integration of CubiCasa, which has quickly established itself as the market’s leading digital floor plan solution. GTCR’s investment builds on the firm’s deep domain expertise across the real estate and mortgage technology ecosystem, including its prior investment in Optimal Blue, a leading digital mortgage marketplace and provider of mortgage data analytics and capital markets technology.

In addition, experienced technology executive Scott Happ has joined Clear Capital’s Board of Directors and will serve as an active Director and advisor to the Company. Mr. Happ brings over 40 years of experience in the mortgage and mortgage technology industry. He previously partnered with GTCR during its investment in Optimal Blue, where he served as CEO from 2016 to 2022. Prior to Optimal Blue, Mr. Happ was the founder and CEO of Mortgagebot, a pioneer in digital mortgage point-of-sale technology.

“Clear Capital’s innovative technology platform, combined with its deep expertise delivering data-driven solutions, positions it as a leader in this rapidly evolving market,” said Michael Hollander, Managing Director at GTCR. “This investment underscores GTCR’s commitment to backing exceptional management teams and leveraging our expertise in technology and financial services to drive transformational growth.”

“Partnering with GTCR represents an exciting new chapter for Clear Capital, enabling us to scale our platform, expand product offerings and continue to provide innovative solutions for the real estate and mortgage industries,” said Mr. Andrews. “Our mission remains the same: to build confidence in real estate decisions to strengthen communities and improve lives. Through this strategic investment, we can build upon this mission even further.” 

“As the real estate landscape continues to undergo rapid change, Clear Capital stands out for its unique technology-driven platform and proven ability to profitably expand and innovate,” said David Lalo, Director at GTCR. “We look forward to partnering with Duane and the entire Clear Capital team to accelerate the Company’s growth trajectory and continue to deliver exceptional value to its customers. We also plan to pursue strategic acquisitions to further expand Clear Capital’s product set.”

Wells Fargo and Houlihan Lokey served as financial advisors to GTCR on the transaction and Simpson Thacher & Bartlett LLP served as GTCR’s legal counsel. American Discovery Capital served as financial advisor to Clear Capital and O’Melveny & Myers LLP served as Clear Capital’s legal counsel.

About GTCR

Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in over 290 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Clear Capital

Clear Capital is a national real estate analytics, data solutions and valuation technology company with a simple purpose: to build confidence in real estate decisions to strengthen communities and improve lives. Our goal is to provide customers with a complete understanding of nearly every U.S. property through our AI-driven analytics, data solutions, valuation services and automated appraisal review platforms. Our commitment to excellence – wherever it leads, whatever it takes® – is embodied by our team members across our brands and has remained steadfast in this pursuit since our first order in 2001.

GTCR Media Contact:
Josh Clarkson / Ryan Smith
[email protected]

Clear Capital Media Contact:
Ross Stevens
Caliber Corporate Advisers for Clear Capital [email protected]

SOURCE GTCR

• Balderton Capital and Peak XV double down on their previous investments in Huspy in its latest funding round
• With six new cities in Spain and a Saudi launch planned, Huspy expects to operate in over 10 cities by end of 2025
• Huspy facilitates over $7 billion in real estate transactions annually in Europe and the Middle East

DUBAI, UAE and MADRID, July 8, 2025 — Huspy (www.huspy.com), the proptech company reshaping home buying experiences from the Middle East to Europe, today announced the close of a $59 million Series B funding round, led by returning investor, Balderton Capital, one of Europe’s leading venture firms. The round also saw participation for a third time from Peak XV (formerly Sequoia Capital India and Southeast Asia), as well as ExBorder Partners, Turmeric Capital, BY Ventures, Dara Management, COTU Ventures and KE Partners. 

With operations in the UAE and Spain, Huspy empowers thousands of real estate agents and mortgage brokers with a market-leading value proposition: high commissions, best-in-class technology and robust infrastructure to serve home buyers and sellers more efficiently.

Huspy facilitates over $7 billion in real estate transactions annually in Europe and the Middle East. The funding will support Huspy’s European expansion, investment in technology and strategic hiring. In Spain, Huspy is operational in Madrid, Valencia, Alicante and Malaga, and will be launching in six additional cities by the end of 2025. In 2024, the company’s Spanish real estate business achieved more than 20x year-on-year growth. This year, Huspy will also expand its Middle East presence by entering the region’s largest economy, the Kingdom of Saudi Arabia, bringing its total footprint to ten cities globally. Over the next four years, the company intends to launch operations across most major cities in Europe and the Middle East.

“We are building a global business with the goal of being present in the majority of European and Middle Eastern cities. We aim to provide the best infrastructure for real estate agents and mortgage brokers, enabling them to grow their businesses and serve home buyers and sellers in the best way possible. After 4 years of investing in our systems, we are now able to operate with a lot of agility allowing us to expand the business at a high growth rate for years to come” said Jad Antoun, Co-Founder and CEO of Huspy.

Huspy is recognised as one of the fastest growing proptechs in the UAE, with thriving operations in Dubai and Abu Dhabi. The company’s mortgage unit is the largest in the UAE, processing over 25% of all residential home financing in Dubai, one of the world’s most active real estate markets.

“We are pleased to renew our partnership with Huspy by leading this round. The team is building technology that modernizes real estate and mortgage businesses, allowing brokers to reap substantial efficiency gains that translate into serving more clients, better,” said Rana Yared, General Partner at Balderton Capital.

To support its expansion, Huspy is hiring across expansion and technology-specific roles. The company has attracted global talent from leading companies in technology and real estate, and has established tech hubs in the UAE and Spain.

About Huspy
Huspy is building the largest home-buying platform in Europe and the Middle East. Huspy empowers real estate agents and mortgage brokers with world-class technology, commissions and infrastructure, and provides homebuyers with seamless access to mortgages, properties and related services through technology and innovation.

www.huspy.com

Photo – https://mma.prnewswire.com/media/2726788/Huspy.jpg

SOURCE Huspy